Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Mutual Funds
Invest in Mutual Funds
Invest in direct mutual funds at zero charges via lump sump investments or SIPs
WANBURY •NSE
Wanbury
₹185.77-1.90 (1.01%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events
Performance
Today’s low
182.21
Today’s high
192.50
52 week low
161.50
52 week high
358.85
Open price
185.86
Previous close
187.67
Live volume
1,28,878
Lower circuit
150.14
Upper circuit
225.20
Fundamentals
Market Cap
₹653Cr
ROE
45.78%
P/E Ratio(TTM)
11.68
EPS(TTM)
15.98
P/B Ratio
4.52
Dividend Yield
0.00%
Industry P/E
48.35
Book Value
41.32
Debt to Equity
1.55
Face Value
10
Financial performance
JUN '26
₹166Cr
+0.70%
₹3.24Cr
-85.07%
050100150200
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
| Revenue growth | Value |
|---|---|
| 1Y (TTM) | +1% |
| 3Y CAGR | +9% |
| Profit growth | Value |
|---|---|
| 1Y (TTM) | -76% |
| 3Y CAGR | +103% |
About
Wanbury Limited is a leading pharmaceutical company specializing in Active Pharmaceutical Ingredients (API) and Formulations. It is one of the world's largest producers of Metformin (anti-diabetic).
The company successfully completed its first commercial shipment of high-potency anaesthetic APIs to the European market from its state-of-the-art Tanaku facility.;
CEO/MD
Mr. Mohan Kumar Rayana
Founded in
1988
NSE symbol
WANBURY
Industry
Shareholding pattern
Similar stocks
| Stock | Mkt price (1D) | 52 week performance | Market cap | P/E ratio | P/B ratio | |
|---|---|---|---|---|---|---|
PfizerPFIZER | ₹3,688.90 -65.80 (1.75%) | 17,211.67 | 23.41 | 4.1 | ||
Caplin Point LaboratoriesCAPLIPOINT | ₹2,249.10 +27.50 (1.24%) | 16,883.72 | 24.9 | 5.01 | ||
Natco PharmaNATCOPHARM | ₹785.15 +0.70 (0.09%) | 15,397.22 | 13.45 | 1.47 | ||
Astrazeneca Pharma IndiaASTRAZEN | ₹6,101.00 +21.50 (0.35%) | 15,192.25 | 89.56 | 17.41 |
Livesquawk •
Wanbury received 9 'No DMF deficiency' letters from the USFDA for its Metformin HCL submissions.
The company is expanding its Metformin business in Saudi Arabia and Mexico.
Livesquawk •
Wanbury launched its BerrySoft Baby product line across several Indian states, expanding into the pediatric dermatology segment.
The company secured GST registrations across five states and obtained CF drug licenses in multiple areas.
Livesquawk •
Wanbury gets EDQM approval for Rivaroxaban API.
USFDA clears DMFs for Paroxetine HCL and Metformin HCL.
2026
11
Aug
Quarterly Result
Release date
29
May
Quarterly & Annual Result
Release date
14
May
Quarterly & Annual Result
Release date
5
Feb
Quarterly Result
Release date
2025
13
Nov
Quarterly Result
Release date
4
Aug
Quarterly Result
Release date
Events calendar
View upcoming events in other stocks